About this Journal Submit a Manuscript Table of Contents
Pulmonary Medicine
Volume 2012 (2012), Article ID 545172, 9 pages
http://dx.doi.org/10.1155/2012/545172
Research Article

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects

Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425-6370, USA

Received 6 May 2011; Accepted 26 August 2011

Academic Editor: Athol Wells

Copyright © 2012 Galina S. Bogatkevich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Galina S. Bogatkevich, Kristin B. Highland, Tanjina Akter, and Richard M. Silver, “The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects,” Pulmonary Medicine, vol. 2012, Article ID 545172, 9 pages, 2012. doi:10.1155/2012/545172